We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-11.09%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.96B
AUM Growth
-$1.12B
Cap. Flow
-$341M
Cap. Flow %
-11.5%
Top 10 Hldgs %
72.49%
Holding
61
New
8
Increased
6
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$239M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$205M
3
MRSN
Mersana Therapeutics
MRSN
+$36.8M
4
ARVN icon
Arvinas
ARVN
+$35.6M
5
SLRN
ACELYRIN
SLRN
+$29.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$419M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$124M
3
BPMC
Blueprint Medicines
BPMC
+$114M
4
RVMD icon
Revolution Medicines
RVMD
+$48.1M
5
DYN icon
Dyne Therapeutics
DYN
+$8.99M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZNW icon
51
Surrozen Inc Warrant
SRZNW
$36.6K
$32.7K ﹤0.01%
66,665
– –
BPMC
52
DELISTED
Blueprint Medicines
BPMC
– –
-1,798,300
Closed -$114M
DYN icon
53
Dyne Therapeutics
DYN
$4.23B
– –
-798,701
Closed -$8.99M
FDMT icon
54
4D Molecular Therapeutics
FDMT
$496M
– –
-66,978
Closed -$1.21M
JANX icon
55
Janux Therapeutics
JANX
$895M
– –
-452,590
Closed -$5.37M
JNJ icon
56
CALL
Johnson & Johnson
JNJ
$643B
– –
-1,700,000
Closed -$281M
KRON
57
DELISTED
Kronos Bio
KRON
– –
-326,780
Closed -$562K
KURA icon
58
CALL
Kura Oncology
KURA
$794M
– –
-500,000
Closed -$5.29M
SRPT icon
59
Sarepta Therapeutics
SRPT
$1.62B
– –
-3,660,798
Closed -$419M
ZNTL icon
60
Zentalis Pharmaceuticals
ZNTL
$323M
– –
-300,000
Closed -$8.46M
PSTX
61
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-676,296
Closed -$1.19M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2023 Portfolio in Review

As of Q3 2023, EcoR1 Capital held 61 positions worth $2.96B, down 27% from $4.08B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital withdrew a net $341M in Q3 2023, closing 10 positions and reducing 4 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $419M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Mirati Therapeutics, Inc. Common Stock worth $250M.

  • EcoR1 Capital's largest Q3 2023 buy was Mirati Therapeutics, Inc. Common Stock: 5,748,399 shares worth $250M.
  • EcoR1 Capital added most to Apellis Pharmaceuticals in Q3 2023, an estimated $239M increase.
  • EcoR1 Capital's biggest Q3 2023 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $124M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2023, selling an estimated $419M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.96B portfolio in Q3 2023.
  • EcoR1 Capital opened 8 new positions and closed 10 in Q3 2023.
  • EcoR1 Capital's portfolio value fell 27% quarter-over-quarter to $2.96B.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.